Skip to content

Percutaneous revascularization for ischemic left ventricular dysfunction

One-paragraph summary

REVIVED-BCIS2 randomized 700 patients with EF ≤35%, extensive coronary disease amenable to PCI, and demonstrable viability to PCI plus medical therapy or medical therapy alone. Death or heart-failure hospitalization occurred in 37.2% versus 38.0% (HR 0.99), and LV function did not improve meaningfully with PCI (Perera 2022, PMID 36027563).

Key findings

  • Viability selection did not identify prognostic PCI benefit.
  • PCI did not improve EF.
  • Early quality-of-life benefit attenuated over time.

Limitations

  • Selected stable patients; not a CABG-versus-PCI trial.
  • Completeness and anatomy differed from surgical trials.
  • Findings do not address urgent ischemia or refractory angina.

Why it matters

REVIVED falsified a widely held inference that viable myocardium plus severe LV dysfunction is sufficient to justify PCI for prognosis.

Cited by wiki pages

  • Revascularization
  • Clinical trials landscape
  • Overview